title: Antitumour activity of a chimeric antibody against the leucocyte antigen CD48.
abstract: Preclinical studies with the murine anti-CD48 antibody, mHuLym3 (IgG2a) have shown it to be a potentially useful therapeutic reagent in the treatment of human leukaemia and lymphoma. For clinical use, humanised antibodies can have a number of advantages over their original murine version, including mediation of higher effector cell function with human cells, longer serum half-life and lower immunogenicity. In this study, we have produced a mouse/human chimeric HuLym3 antibody (cHuLym3) where the murine antibody constant regions have been replaced with human constant regions. We report the production and preclinical characterisation of the antibody, cHuLym3, with potent in vitro and in vivo antitumour activity. The genes encoding the variable heavy and light chains were amplified by the polymerase chain reaction, sequenced and cloned into eukaryotic expression vectors containing the human light- and heavy-chain constant regions (kappa and IgG1). The chimeric and murine HuLym3 antibodies had similar cell-binding specificity and affinity. In the human Raji cell severe combined immunodeficient mouse model the i.v. injection of cHuLym3 and mHu-Lym3 produced similar antitumour responses. Doses of cHuLym3 and mHuLym3 (100 microg) on days 1, 2 and 4 after i.v. Raji cell injection produced a 40% longer time to hind-leg paralysis than when a control antibody was used. cHuLym3 had more potent activity than mHuLym3 in antibody-dependent cellular cytotoxicity (ADCC) assays in vitro, with human peripheral blood mononuclear cells as effectors. Up to 60% specific cell lysis was observed with cHuLym3 in ADCC assays. These properties suggest that anti-CD48 antibodies may be useful in the treatment of a number of diseases including lymphoid leukaemias and lymphoma.
authors.affiliation: CRC for Biopharmaceutical Research Ltd., Darlinghurst, NSW, Australia.
authors.forename: H
authors.initials: H
authors.lastname: Sun
authors.forename: J C
authors.initials: JC
authors.lastname: Biggs
authors.forename: G M
authors.initials: GM
authors.lastname: Smith
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000235:genetics / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D000071178:CD48 Antigen; D003001:Cloning, Molecular; D005803:Genes, Immunoglobulin; D006801:Humans; D007111:Immunity, Cellular; D007135:Immunoglobulin Variable Region; D007167:Immunotherapy; D008223:Lymphoma / Q000628:therapy*; D051379:Mice; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000970:Antineoplastic Agents; D000071178:CD48 Antigen; C000604065:CD48 protein, human; C000604066:Cd48 protein, mouse; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins